Qiagen N.V. (1QGEN.MI) Stock Price, News, Quote & History
This article provides detailed financial information and an overview of Qiagen N.V. (1QGEN.MI), a company specializing in sample to insight solutions for molecular diagnostics and life sciences. It includes current stock performance, key financial metrics, company description, and recent performance compared to the S&P 500. The content highlights Qiagen's offerings in sample technology, immune response, oncology, and bioinformatics.
QIAGEN N.V. (QIA): Bank of America Holds 4.95% Voting Rights
Bank of America Corporation has informed QIAGEN N.V. (QIA) that it holds 4.95% of QIAGEN's voting rights and capital interest as of September 28, 2026. This stake is held through a combination of shares, options, and swaps. An AI analyst notes this significant institutional position could influence governance and liquidity, with the mix of derivatives indicating potential tactical positioning.
QIAGEN N.V. (QIA) AFM Discloses Bank of America Voting Rights Notice
QIAGEN N.V. (QIA) announced that the Dutch AFM (Authority for the Financial Markets) disclosed a voting rights notification from Bank of America Corporation, dated September 28, 2026, related to QIAGEN. This regulatory flag indicates a potential change in ownership position, which could affect the company's float and liquidity. QIAGEN relayed the notice but disclaimed responsibility for its accuracy.
QIAGEN jumps as new FDA clearance bolsters its syndromic-testing growth story
QIAGEN (QGEN) saw a 6.6% stock increase following FDA clearance for a new QIAstat-Dx bloodstream infection panel, which expands its U.S. testing capabilities. This development, coupled with better-than-expected quarterly results and reaffirmed full-year guidance, has instilled renewed investor confidence. The new panel enhances the company's ability to identify bacteria and antimicrobial resistance markers, strengthening its syndromic-testing growth platform.
Qiagen (NYSE:QGEN) Shares Climb 7.7% - What's Next?
Qiagen (NYSE:QGEN) shares climbed 7.7% to $45.29, with approximately 1.59 million shares traded. This surge follows the company's recent exceeding of quarterly expectations, reporting $0.62 EPS against an estimated $0.60, and revenue of $535.04 million, surpassing the $527.50 million forecast. Analyst sentiment is mixed, with a consensus "Hold" rating, though some analysts like JPMorgan have increased price targets.
QIAGEN N.V. (QIA): Bank of America Discloses 5.15% Holding
Bank of America has disclosed a 5.15% stake in QIAGEN N.V. (QIA), as notified by the Dutch AFM. This stake, effective as of September 25, 2026, includes both real and potential holdings through various subsidiaries. The disclosure highlights BoA's significant ownership and the mix of direct and derivative-based influence on QIAGEN.
QIAGEN N.V. (QIA) Notified of Bank of America Voting Rights Filing
QIAGEN N.V. (QIA) announced that the Dutch AFM disclosed a voting rights notification from Bank of America Corporation, dated September 25, 2026. This is a standard regulatory disclosure indicating a change in reported voting rights by a major institution, with potential market impact if specific thresholds are crossed. QIAGEN disclaimed responsibility for the accuracy of the details, which are available in the AFM register.
QIAGEN Completes U.S. QIAstat-Dx Bloodstream Infection Portfolio With FDA Clearance of New Bacteria Detection Panel
QIAGEN has completed its U.S. QIAstat-Dx bloodstream infection portfolio with FDA clearance of a new panel that detects gram-negative bacteria and antibiotic resistance markers in about an hour. This new panel, combined with an existing one for gram-positive bacteria and fungi, offers comprehensive detection of 33 pathogen targets and 28 antimicrobial resistance markers. The rapid results are crucial for timely treatment decisions in sepsis, a life-threatening condition caused by bloodstream infections.
Qiagen grounds drug discovery agents in curated knowledge
Qiagen N.V. is emphasizing the critical role of human-curated knowledge in AI-driven drug discovery, arguing that trustworthy information is as important as advanced models. According to Iman Bhattacharya, Qiagen's senior global product marketing manager, their approach, which includes over 25 years of manual biomedical data curation by experts, helps prevent AI agents from "hallucinating" or providing untraceable results. The company has also partnered with Nvidia Corp. to enhance graph-based AI for drug discovery, aiming to integrate curated knowledge into a complete and accurate system for biopharma companies.
QIAGEN says FDA cleared second QIAstat‑Dx bloodstream panel
QIAGEN N.V. announced that the U.S. FDA cleared its second QIAstat-Dx bloodstream infection panel, a gram-negative assay that completes its U.S. bloodstream infection portfolio. This new panel identifies 13 bacterial targets and 18 antimicrobial resistance markers, following the clearance of its first panel (covering gram-positive bacteria and fungi) on August 10. The company's QIAstat-Dx range can identify pathogens and resistance markers in about an hour after a blood culture turns positive, offering a rapid diagnostic tool.
A new infection test finds 13 bacteria and 18 signs of antibiotic resistance in about an hour.
QIAGEN has announced that U.S. laboratories now have access to its complete QIAstat-Dx bloodstream infection portfolio after the FDA cleared a new panel for gram-negative bacteria and antibiotic resistance markers. This new panel complements an existing one for gram-positive bacteria and fungi, together covering 33 pathogen targets and 28 antimicrobial resistance markers, delivering results in about an hour. This rapid identification is crucial for guiding treatment decisions for bloodstream infections, which can lead to sepsis and high mortality rates.
QIAGEN Completes U.S. QIAstat-Dx Bloodstream Infection Portfolio With FDA Clearance of New Bacteria Detection Panel
QIAGEN has announced the completion of its U.S. QIAstat-Dx bloodstream infection portfolio with the FDA clearance of a new panel for detecting gram-negative bacteria and antibiotic resistance markers. This new panel, alongside a previously cleared one for gram-positive bacteria and fungi, offers rapid identification of 33 pathogen targets and 28 antimicrobial resistance markers in about one hour. This advancement aims to provide clinicians with timely information to guide treatment decisions for life-threatening sepsis.
Qiagen N.V. (NYSE:QGEN) Stock Has Consensus Target Price of $43.51
Qiagen N.V. (NYSE:QGEN) has received an average "Hold" rating from 14 brokerages, with a consensus 12-month price target of $43.51, slightly below its current trading price of $44.15. The company recently exceeded quarterly earnings and revenue expectations, reporting $0.62 per share on $535.04 million in revenue. Institutional investors hold approximately 70% of Qiagen's stock.
Qiagen N.V. (QGEN) Stock Price, News, Quote & History
This article provides a detailed financial overview of Qiagen N.V. (QGEN), including its current stock price, historical performance, key financial metrics, and analyst recommendations. It outlines the company's business in diagnostics and research, offering various sample to insight solutions globally. The report also highlights recent earnings, performance against benchmarks, and important valuation measures.
Warren Wise decodes Qiagen’s DNA
The article summarizes an analysis by "Warren Wise" of Qiagen N.V.'s financial health and future prospects. It highlights Qiagen's strong recurring revenues and cash flow but raises questions about its R&D investment strategy given ambitious growth targets. The analysis, presented in the "Warrens Watchlist" podcast, ultimately gives Qiagen a score of 4 out of 5, indicating a generally convincing equity story with some areas requiring close monitoring.
Qiagen N.V. $QGEN Holdings Raised by State Street Corp
State Street Corp increased its holdings in Qiagen N.V. (NYSE:QGEN) by 4.5% during the second quarter, bringing its total stake to 2.18 million shares valued at approximately $85.4 million. Qiagen exceeded analyst expectations for its recent quarterly earnings, reporting adjusted EPS of $0.62 against a $0.60 consensus and revenue of $535.0 million against estimates of $527.5 million, while maintaining its fiscal 2026 EPS guidance. Despite shares opening higher, analysts currently maintain an average "Hold" rating with a consensus price target slightly below the current share price.
QIAGEN Launches QIAmini to Automate Small-Batch Sample Preparation
QIAGEN N.V. has launched QIAmini, a compact automated system designed to streamline sample preparation for research laboratories handling smaller batches. This system automates DNA and RNA extraction and purification, significantly reducing hands-on time by over 80%. QIAmini is the third sample preparation system introduced by QIAGEN in 2026, expanding its automation portfolio to serve diverse laboratory needs from small-scale research to high-throughput clinical testing.
Here's Why You Should Hold QIAGEN Stock in Your Portfolio for Now
QIAGEN (QGEN) is positioned for growth due to its expanding test menu and strategic collaborations, which support assay development and generate recurring revenue. However, the company faces headwinds from cautious customer spending, weaker research funding, and intense competition, which could impact near-term growth and adoption of new platforms. Despite these challenges, its earnings yield outperforms the industry, making it a stock to hold for now.
Qiagen N.V. : Deutsche Bank remains its Buy rating
Deutsche Bank analyst Jan Koch has reiterated a Buy rating for Qiagen N.V., maintaining a target price of EUR 47. This news was published on September 24, 2026, at 07:18 am EDT. Qiagen N.V. specializes in products for DNA and RNA isolation and purification, with significant operations in the US and Europe.
QIAGEN N.V. (QIA) Receives AFM Notice on BlackRock Voting Rights
QIAGEN N.V. (QIA) has reported that the Dutch Authority for the Financial Markets (AFM) disclosed a notification regarding BlackRock, Inc.'s voting rights related to QIAGEN, dated September 18, 2026. This is a routine regulatory ownership disclosure, and its implications depend on the direction and size of the change, which are not detailed in the report.
QIAGEN N.V. (QIA) Reports AFM Disclosure of BlackRock Voting Rights
QIAGEN N.V. (QIA) announced that the Dutch AFM disclosed a BlackRock, Inc. notification detailing its significant stake in Qiagen. As of September 18, 2026, BlackRock holds a total capital interest of 11.42% and voting rights of 12.83% in Qiagen through various entities and instruments. This disclosure highlights BlackRock's substantial influence over the company's ownership dynamics and governance.
QIAGEN N.V. (QIA) Notes AFM Disclosure on BlackRock Voting Rights
QIAGEN N.V. (QIA) has reported that the Dutch Authority for the Financial Markets (AFM) disclosed a notification regarding BlackRock, Inc.'s voting rights in QIAGEN, dated September 18, 2026. This is a routine regulatory ownership disclosure, and an AI Analyst noted that its implications depend on the direction and size of the change in BlackRock's stake. The details of this notification are available on the AFM register.
QIAGEN N.V. (QIA) Discloses AFM Notice on BlackRock Voting Rights
QIAGEN N.V. (QIA) announced that the Dutch AFM received a notification from BlackRock, Inc., revealing that BlackRock holds a total capital interest of 11.42% and voting rights of 12.83% in Qiagen. These holdings are distributed across various entities and instruments, including CFDs. The disclosure highlights a significant institutional stake that could influence company governance, though its immediate impact depends on future changes or activist intent.
QIAGEN N.V. (QIA) Notified of 2.99% Voting Rights by Millennium
QIAGEN N.V. (QIA) has been notified by the AFM that Millennium International Management LP disclosed a 2.99% holding in the company's voting rights and capital as of September 16, 2026. This stake includes 3.44 million ordinary shares, 2.26 million shares via swap, and 477.8K settlement options. An AI analyst views this as a mid-cycle ownership disclosure, signaling institutional positioning rather than a fundamental shift, and suggests that a larger catalyst would require crossing higher thresholds or activist intentions.
QIAGEN N.V. (QIA) Notes AFM Voting Rights Filing by Goldman Sachs
QIAGEN N.V. announced that the Dutch AFM disclosed a voting rights notification concerning the company, filed by Goldman Sachs Group Inc., dated September 16, 2026. QIAGEN relays this notice from the AFM register but disclaims responsibility for its accuracy. This filing indicates a potential change in ownership dynamics for QIAGEN.
QIAGEN N.V. (QIA) AFM Posts Voting Rights Notice
QIAGEN N.V. (QIA) reported a voting rights notification from the Dutch AFM concerning Millennium International Management LP, dated September 16, 2026. This notification indicates a regulatory ownership update. QIAGEN N.V. clarified that it is not responsible for the accuracy of the notification and refers to the AFM register for details.
Qiagen stock holds at USD 44.78 below its yearly high
Qiagen N.V. stock closed at USD 44.78 on September 22, 2026, which is USD 13.04 below its 52-week high of USD 57.82 and USD 12.25 above its 52-week low of USD 32.53. The stock gained 3.4 percent on September 21, 2026. The 52-week range provides a clear valuation context for the current share price.
A Look at Qiagen NV (QGEN) After 3.4% Gain -- GF Value $49.88 vs Price $44.78
Qiagen NV (QGEN) shares recently rose 3.4% to $44.78 and are considered "Modestly Undervalued" according to GuruFocus' GF Value estimate of $49.88, offering a 10.2% margin of safety. The company boasts a strong GF Score™ of 75/100, particularly in valuation (10/10), although growth (4/10) is an area for investor consideration. While gurus show mixed sentiment, the absence of insider transactions over the past year suggests stable insider confidence in the company's prospects.
QIAGEN Calls Extraordinary General Meeting for Appointment of Jonathan M. Pratt to Managing Board
QIAGEN N.V. announced an Extraordinary General Meeting of Shareholders on November 6, 2026, to vote on the appointment of Jonathan M. Pratt to its Managing Board. Pratt recently joined QIAGEN as CEO. Shareholders will also vote on the discharge of Thierry Bernard, who stepped down as CEO and Managing Board member on September 1, 2026.
Qiagen N.V. (QGEN) Stock Report: A Healthcare Giant With A Potential Upside Of 6.78%
Qiagen N.V. (QGEN) is highlighted as a significant healthcare player with a potential upside of 6.78%, based on an average target price of $46.27 compared to its current stock price of $43.33. The company, specializing in molecular diagnostics, demonstrates strong financial health with $372.9 million in free cash flow and a return on equity of 11.93%. Analyst sentiment is largely positive, suggesting a stable outlook for future growth in the diagnostics and research industry.
QIAGEN N.V. (XETR:QIA) Discloses BlackRock Holding at 11.58% Capital, 12.99% Votes
QIAGEN N.V. (XETR:QIA) announced that BlackRock holds an 11.58% capital interest and 12.99% voting rights in the company, as disclosed by the AFM on September 14, 2026. This significant institutional stake, which includes both real and potential holdings like CFDs, reinforces known investor interest but is not considered a new strategic move. Further actions like increased activism or board changes would be needed to act as a larger catalyst for the stock.
QIAGEN Calls Extraordinary General Meeting for Appointment of Jonathan M. Pratt to Managing Board
QIAGEN N.V. announced it will hold an Extraordinary General Meeting of Shareholders on November 6, 2026, to vote on the appointment of Jonathan M. Pratt to its Managing Board as CEO. Shareholders will also vote on the discharge of former CEO Thierry Bernard. Related materials for the meeting will be available on QIAGEN's Investor Relations website.
Qiagen NV (QGEN) Shares Surge 3.5% -- What GF Score of 75 Tells Investors
Qiagen NV (QGEN) shares surged 3.5% to $44.38, and the stock is currently assessed as modestly undervalued by GuruFocus's GF Value™ with a fair value of $49.41. The company holds a GF Score™ of 75/100, indicating above-average performance, particularly strong in valuation (10/10) and profitability (7/10), despite lower growth potential. While gurus are active, adding and trimming positions, there have been no insider transactions in the past year.
Qiagen Shares Rise 4% Following Report of Private Equity Takeover Interest
Shares of Qiagen (NYSE:QGEN) rose 4% after a report from German publication Manager Magazin indicated that several private equity firms, including TPG and Bain Capital, are considering takeover bids for the molecular testing company. Other firms like KKR, EQT, and Advent were also named as potential suitors. While the report provided no specific details on offer prices or timelines, and neither Qiagen nor the named firms have confirmed any discussions, investors reacted positively to the prospect of an acquisition.
Qiagen N.V. $QGEN Stock Position Raised by Engineers Gate Manager LP
Engineers Gate Manager LP significantly increased its stake in Qiagen (NYSE:QGEN) by 107.7% in the second quarter, bringing its holdings to 74,567 shares valued at $2.9 million. This increase follows Qiagen's strong quarterly performance, where it exceeded analyst expectations for earnings and revenue, reporting $0.62 EPS and $535.04 million in revenue. Despite a consensus "Hold" rating from analysts with an average price target of $43.51, institutional investors collectively own 70% of the company's stock, reflecting continued interest.
36,400 Shares in Qiagen N.V. $QGEN Purchased by WINTON GROUP Ltd
WINTON GROUP Ltd recently acquired 36,400 shares of Qiagen N.V. (NYSE:QGEN) for approximately $1.42 million during the second quarter. This purchase contributes to the roughly 70% institutional ownership of Qiagen's stock. The company exceeded its quarterly earnings expectations with an EPS of $0.62 and revenue of $535.04 million, while analysts currently maintain a consensus "Hold" rating with an average price target of $43.51.
Groupe la Francaise Has $3.25 Million Stake in Qiagen N.V. $QGEN
Groupe la Francaise reduced its stake in Qiagen N.V. by 37% in the second quarter, now holding 83,911 shares valued at approximately $3.25 million. Qiagen exceeded analyst expectations with its latest quarterly earnings and revenue, reporting $0.62 EPS and $535.04 million in revenue. The company maintains a "Hold" rating from analysts with an average price target of $43.93, while institutional investors and hedge funds collectively own about 70% of its stock.
New CEO took over the reins
Jonathan M. Pratt has taken over as CEO of Qiagen N.V., succeeding Thierry Bernard who led the company for nearly seven years. Pratt brings over 25 years of international leadership experience in the life sciences and healthcare sectors, having previously served in senior roles at Filtration Group, Waters Corporation, and Beckman Coulter Life Sciences. Bernard will assist with the transition until the end of the year.
Public Employees Retirement System of Ohio Purchases New Shares in Qiagen N.V. $QGEN
Public Employees Retirement System of Ohio has acquired 72,503 shares of Qiagen N.V. (NYSE:QGEN) during the second quarter, valued at approximately $2.84 million. This purchase is part of broader institutional interest, with hedge funds and other institutional investors owning about 70% of Qiagen's stock. Qiagen has recently exceeded quarterly earnings expectations, though analyst sentiment remains cautious with a consensus "Hold" rating and a price target close to its current share price.
Qiagen N.V. (NYSE:QGEN) Receives Average Recommendation of "Hold" from Analysts
Qiagen N.V. (NYSE:QGEN) has received a consensus "Hold" recommendation from analysts, with nine out of fourteen rating the stock a hold. The average 12-month price target is $43.93, slightly above its current share price of $43.35. The company recently exceeded quarterly expectations, reporting earnings of $0.62 per share and revenue of $535.04 million.
QIAGEN Launches QIAsymphony Connect for Automated Nucleic Acid Extraction
QIAGEN has commercially launched QIAsymphony Connect, an IVD-compliant platform for automated clinical nucleic acid extraction. This new system, building on the existing QIAsymphony, standardizes extraction across various assay workflows and supports applications like liquid biopsy. It features integrated liquid handling, prefilled IVD reagent cartridges, and automated load checks to enhance workflow automation, traceability, and process safety for high-throughput molecular testing.
Two potential buyers begin formal due diligence in Qiagen sales process - report (QGEN:NYSE)
Two potential buyers have initiated formal due diligence on Qiagen (QGEN) as part of the molecular diagnostics provider's strategic review. The due diligence process began last week, with discussions centering on a potential sale price of approximately $50 per share. This information comes from a CTFN report published on Tuesday.
Qiagen stock dips as CEO transition and FDA panel clearance reshape the 2026 story
Qiagen's stock has dipped into the low-$40s following a CEO transition, a Q2 2026 earnings beat, and FDA clearance for a rapid bloodstream infection panel. Investors are focusing on governance and capital allocation questions as the new CEO takes over amidst a strategic review. Despite the stock dip, the company reaffirmed its full-year 2026 targets for double-digit growth and an 8-10% EBIT margin, supported by a stronger-than-expected Q2 performance and a product portfolio resilient to Chinese diagnostics pricing reforms.
Qiagen stock slips as CEO change and Q2 2026 beat keep deal story alive
Qiagen's stock has declined despite exceeding Q2 2026 financial guidance and reaffirming full-year targets, primarily due to investor uncertainty surrounding the upcoming CEO transition to Jonathan M. Pratt and ongoing strategic review for a potential sale. The company's Q2 revenue was $535.04 million with a net income of $103.4 million, demonstrating solid profitability, while a new FDA-cleared diagnostic panel for bloodstream infections further strengthens its product portfolio. Despite the short-term stock volatility, valuation models suggest the stock is trading at a discount to its intrinsic value, positioning it in the middle of its 52-week range.
Qiagen NV (QGEN) Stock Down 5.2% -- Now Undervalued? GF Score: 7
Qiagen NV (QGEN) shares recently dropped by 5.2% to $41.78, yet GuruFocus's GF Value™ indicates the stock is 15.3% undervalued with a fair value of $49.34. The company holds a GF Score™ of 70/100, reflecting strong financial health and valuation, despite lower growth and momentum scores. While there's no recent insider trading, three gurus have added to their positions, suggesting long-term potential for investors.
QIAGEN Slides as CEO Change Keeps Focus on Leadership Transition and Strategic Review
QIAGEN N.V. (QGEN) experienced a 3.3% stock drop following the announcement of Jonathan M. Pratt as its new CEO, replacing Thierry Bernard, while the company's strategic review remains ongoing. Investors are likely reacting to this leadership change as a new layer of uncertainty, despite QIAGEN reaffirming its outlook for Q3 and full-year 2026. This sentiment prevails even though the company had recently exceeded its Q2 2026 outlook.
Qiagen names Jonathan Pratt as CEO amid takeover talks By Investing.com
Qiagen N.V. has appointed Jonathan M. Pratt as its new CEO, effective September 1, 2026. Pratt, who brings over 25 years of experience in life sciences, will succeed Thierry Bernard. The announcement comes as Qiagen continues discussions with potential buyers, including EQT AB and KKR & Co., and has opened a data room for due diligence.
Qiagen names Jonathan Pratt as CEO amid takeover talks
Qiagen N.V. announced that Jonathan M. Pratt will become CEO on September 1, 2026, amidst ongoing discussions with potential buyers. Pratt brings over 25 years of experience in life sciences and laboratory technologies, having previously led Filtration Group and held senior roles at Waters Corporation and Beckman Coulter Life Sciences. The appointment follows a comprehensive search, with Pratt succeeding Thierry Bernard while the company continues to evaluate takeover opportunities, including interest from EQT AB and KKR & Co.
QIAGEN Appoints Jonathan M. Pratt as Chief Executive Officer
QIAGEN N.V. announced the appointment of Jonathan M. Pratt as its new Chief Executive Officer, effective September 1, 2026. Pratt brings over 25 years of international leadership experience in life sciences and laboratory technologies, having previously led Filtration Group and held senior roles at Waters Corporation and Beckman Coulter Life Sciences. Thierry Bernard will step down but support the transition, while QIAGEN reaffirms its outlook for Q3 and full-year 2026 and continues its strategic review.
How FDA Clearance of QIAstat-Dx Sepsis Panel Will Impact Qiagen (QGEN) Investors
Qiagen recently received FDA clearance for its QIAstat-Dx BCID GPF Plus AMR Panel, expanding its QIAstat-Dx platform to four infectious disease areas and improving sepsis diagnostics. This development is expected to strengthen Qiagen's investment narrative by deepening the adoption and use of its molecular diagnostics and automation platforms, despite ongoing macro volatility and competition. While analysts have varied outlooks, this clearance provides a new clinically important use case that could drive future growth for the company.
